International Biotechnology (LON:IBT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

International Biotechnology (LON:IBT)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 686.23 ($8.57) and traded as high as GBX 710 ($8.87). International Biotechnology shares last traded at GBX 710 ($8.87), with a volume of 48,839 shares changing hands.

International Biotechnology Stock Up 0.8 %

The company has a quick ratio of 0.32, a current ratio of 0.46 and a debt-to-equity ratio of 9.66. The stock has a 50 day simple moving average of GBX 693.87 and a 200 day simple moving average of GBX 686.65. The stock has a market cap of £264.63 million, a price-to-earnings ratio of 1,491.67 and a beta of 0.21.

International Biotechnology (LON:IBT) last announced its earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) earnings per share (EPS) for the quarter. International Biotechnology had a net margin of 75.33% and a return on equity of 6.25%. As a group, analysts expect that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year.

International Biotechnology Increases Dividend

The business also recently announced a dividend, which was paid on Friday, January 24th. Investors of record on Thursday, December 19th were given a dividend of GBX 15.56 ($0.19) per share. This is a boost from International Biotechnology’s previous dividend of $14.50. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 2.21%. International Biotechnology’s payout ratio is presently 6,041.67%.

Insider Activity at International Biotechnology

In other International Biotechnology news, insider Katherine Cornish-Bowden acquired 1,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were acquired at an average price of GBX 713 ($8.90) per share, with a total value of £10,695 ($13,353.73). 4.18% of the stock is owned by insiders.

About International Biotechnology

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.